Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 113Colorectal Neoplasms 73Stomach Neoplasms 48Pancreatic Neoplasms 45Rectal Neoplasms 40Neoplasms 29Neoplasm Metastasis 29Colonic Neoplasms 18Esophageal Neoplasms 16Triple Negative Breast Neoplasms 13Adenocarcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Gallbladder Neoplasms 9Bile Duct Neoplasms 8Brain Neoplasms 7Adenocarcinoma Of Esophagus 7Liver Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Cholangiocarcinoma 5Breast Neoplasms, Male 5Somatostatinoma 4Head and Neck Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Gastrointestinal Neoplasms 3Gastrinoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Solid Tumor 2

Interventions

regorafenib 1napabucasin 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Gastrointestinal Cancer × Capecitabine × Clear all
NCT02024607 2023-11-15

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
495 enrolled 18 charts
Gastrointestinal

Advanced Gastrointestinal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡